(US) – The European Medicines Agency (EMA) said that it had initiated a rolling review of data on antibodies bamlanivimab and etesemivab developed by US company Eli Lilly to treat COVID-19. EMA also informed that it was yet to evaluate the full dataset and therefore, it was too early to draw any conclusions regarding the benefit-risk balance of the medicines.
A US Air Force man is in critical condition after setting himself on fire in front of the Israel embassy in Washington. On Sunday afternoon, the US Secret...
Read more